Biospecimen collection for cancer research
Official title: Arizona Cancer Center Biospecimen Repository
Run by University of Arizona · NCT00896935 · Data updated 2026-11-12
This study is collecting and storing samples from patients with pancreatic cancer to help researchers learn more about the disease and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | University of Arizona Academic / other |
| Locations | 1 site (Tucson, Arizona) |
| Status | Recruiting |
| Started | August 1, 2006 |
| Main results expected | July 2030 |
| Study ends | July 2030 |
| Registry record updated | April 6, 2026 |
| Trial ID | NCT00896935 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with pancreatic cancer who are undergoing surgery or procedures at the Arizona Cancer Center or University Medical Center.
✕Probably not a fit
Patients who are not undergoing treatment for pancreatic cancer or those not receiving care at the participating institutions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research collects and stores tumor, tissue, and blood samples from patients with pancreatic cancer to facilitate future cancer studies. The objective is to provide cancer researchers with access to a diverse range of biospecimens for translational research. Samples are collected from both cancerous and non-cancerous tissues, along with relevant clinical data, ensuring quality-controlled storage and management. The study aims to create a comprehensive database that supports ongoing cancer research and improves understanding of the disease.
Why it matters
Potential benefit: If successful, this initiative could enhance cancer research and lead to improved treatment options for patients.
How similar studies have gone: Other studies utilizing biospecimen repositories have shown success in advancing cancer research, making this approach well-established.
Who can join: the full rules
Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS: * Patient who is seen at the Arizona Cancer Center or University Medical Center and will undergo any surgery or procedure for cancer PATIENT CHARACTERISTICS: * NA PRIOR CONCURRENT THERAPY: * NA As this is a biospecimen repository, participation is open to all cancer patients being treated at the Arizona Cancer Center or University Medical Center by investigators on this protocol.
Where it's running
-
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States Recruiting
Study contacts
- Principal investigator: Setsuko K. Chambers, MD — University of Arizona
- Study coordinator: Arizona Cancer Center at University of Arizona Health Sciences
- Phone: 520-626-0950
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Diagnosing malignant pleural effusion with the EPISEEK-MPE liquid biopsy
A test called EPISEEK-MPE is being checked to see if it can tell cancer from non-cancer pleural effusions using fluid already removed for care.
-
Linking social care with healthcare to help manage chronic diseases
This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.
-
Apixaban vs Warfarin for a Left Ventricular Thrombus
This study tests whether apixaban can more conveniently and safely dissolve a left ventricular blood clot compared with warfarin.
-
Breathing for Two: Can inspiratory muscle training help with blood pressure in late pregnancy?
This study tests whether a home-based inspiratory muscle strength training program can safely lower blood pressure in pregnant people in their third trimester.
-
Comparative test of PAP therapy, a dental device, and atomoxetine-oxybutynin for adults with obstructive sleep apnea
This study tests three options for obstructive sleep apnea to see which works best and is easiest for patients to use.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.